Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (
The wholesale acquisition cost of Mayzent is $88,500 per year. Mavenclad is $99,500 annually. Even for those with insurance, copayments of up to 28-30% mean that out of pocket costs will be thousands of dollars per month.
Drug treatments for MS have been climbing an expensive staircase for a number of years. Take the first disease-modifying agent approved,
Because what good is a drug that few people can afford? And the nature of MS requires that disease-modifying treatments be started as soon as possible to ensure the best chance of forestalling relapses. For a disease with no cure, characterized by its on-again, off-again nature, this puts people with MS in the distressing position of having to determine just how much their extra life is worth.
It is very hard to justify what people with MS have to pay for their medications, even taking into account the cost of bringing a new drug to market. There are at least a million other Americans who would agree.
For more information about MS see here